Gain of function SCN1A disease‐causing variants: Expanding the phenotypic spectrum and functional studies guiding the choice of effective antiseizure medication
Epilepsia · 2023
DOI: 10.1111/epi.17509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsia, 2023. Verfasst von Sara Matricardi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Child Neurology and Psychiatry Unit, "G. Salesi" Children's Hospital, Ospedali Riuniti Ancona, Ancona, Italy. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Epilepsies, Partial, NAV1.1 Voltage-Gated Sodium Channel. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Objective
This study was undertaken to refine the spectrum of SCN1A epileptic disorders other than Dravet syndrome (DS) and genetic epilepsy with febrile seizures plus (GEFS+) and optimize antiseizure management by correlating phenotype–genotype relationship and functional consequences of SCN1A variants in a cohort of patients.
Methods
Sixteen probands carrying SCN1A pathogenic variants were ascertained via a national collaborative network. We also performed a literature review including individuals with SCN1A variants causing non‐DS and non‐GEFS+ phenotypes and compared the features of the two cohorts. Whole cell patch clamp experiments were performed for three representative SCN1A pathogenic variants.
Results
Nine of the 16 probands (56%) had de novo pathogenic variants causing developmental and epileptic encephalopathy (DEE) with seizure onset at a median age of 2 months and severe intellectual disability. Seven of the 16 probands (54%), five with inherited and two with de novo variants, manifested focal epilepsies with mild or no intellectual disability. Sodium channel blockers never worsened seizures, and 50% of patients experienced long periods of seizure freedom. We found 13 SCN1A missense variants; eight of them were novel and never reported. Functional studies of three representative variants showed a gain of channel function. The literature review led to the identification of 44 individuals with SCN1A variants and non‐DS, non‐GEFS+ phenotypes. The comparison with our cohort highlighted that DEE phenotypes are a common feature. Significance The boundaries of SCN1A disorders are wide and still expanding. In our cohort, >50% of patients manifested focal epilepsies, which are thus a frequent feature of SCN1A pathogenic variants beyond DS and GEFS+. SCN1A testing should therefore be included in the diagnostic workup of pediatric, familial and nonfamilial, focal epilepsies. Alternatively, non‐DS/non‐GEFS+ phenotypes might be associated with gain of channel function, and sodium channel blockers could control seizures by counteracting excessive channel function. Functional analysis evaluating the consequences of pathogenic SCN1A variants is thus relevant to tailor the appropriate antiseizure medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Child Neurology and Psychiatry Unit, "G. Salesi" Children's Hospital, Ospedali Riuniti Ancona, Ancona, Italy.
- Department of Pediatrics, University of Chieti, Chieti, Italy.
- Côte d'Azur University, Valbonne-Sophia Antipolis, France.
- CNRS UMR7275, Institute of Molecular and Cellular Pharmacology (IPMC), Valbonne-Sophia Antipolis, France.
- Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Full member of European Reference Network EpiCARE, Rome, Italy.
- Neurology Unit, Department of Neuroscience, University of Padua, Padua, Italy.
ORCID-Profile: Sara Matricardi, Sandrine Cestèle, Francesca Felicia Operto, Stefano Sartori, Nicola Specchio, Federico Vigevano, Carla Marini, Massimo Mantegazza
Zitieren
APA
Matricardi, S., Cestèle, S., Trivisano, M., Kassabian, B., Leroudier, N., Vittorini, R., Nosadini, M., Cesaroni, E., Siliquini, S., Marinaccio, C., Longaretti, F., Podestà, B., Operto, F. F., Luisi, C., Sartori, S., Boniver, C., Specchio, N., Vigevano, F., Marini, C., & Mantegazza, M. (2023). Gain of function SCN1A disease‐causing variants: Expanding the phenotypic spectrum and functional studies guiding the choice of effective antiseizure medication. Epilepsia. https://doi.org/10.1111/epi.17509
Vancouver
Matricardi S, Cestèle S, Trivisano M, Kassabian B, Leroudier N, Vittorini R, et al. Gain of function SCN1A disease‐causing variants: Expanding the phenotypic spectrum and functional studies guiding the choice of effective antiseizure medication. Epilepsia. 2023. doi:10.1111/epi.17509
BibTeX
@article{Matricardi2023,
author = {Matricardi, Sara and Cestèle, Sandrine and Trivisano, Marina and Kassabian, Benedetta and Leroudier, Nathalie and Vittorini, Roberta and Nosadini, Margherita and Cesaroni, Elisabetta and Siliquini, Sabrina and Marinaccio, Cristina and Longaretti, Francesca and Podestà, Barbara and Operto, Francesca Felicia and Luisi, Concetta and Sartori, Stefano and Boniver, Clementina and Specchio, Nicola and Vigevano, Federico and Marini, Carla and Mantegazza, Massimo},
title = {Gain of function SCN1A disease‐causing variants: Expanding the phenotypic spectrum and functional studies guiding the choice of effective antiseizure medication},
journal = {Epilepsia},
year = {2023},
doi = {10.1111/epi.17509}
}
EUVIMED